申请人:Burns Christopher John
公开号:US20100130447A1
公开(公告)日:2010-05-27
The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.
本发明涉及抑制激酶的吡啶或吡嗪类化合物。特别地,本发明的化合物抑制III类PTK受体家族的成员,如FMS(CSF-IR)、c-KIT、PDGFRβ、PDGFRα或FLT3和KDR、SRC、EphA2、EphA3、EphA8、FLT1、FLT4、HCK、LCK、PTK5(FRK)、SYK、DDR1和DDR2以及RET。本发明的化合物在治疗激酶相关疾病方面具有用途,包括免疫和炎症性疾病;增生性疾病,包括癌症和涉及新生血管形成的疾病;肾脏疾病;骨重塑性疾病;代谢性疾病;以及血管疾病。